Sanofi pipeline worries dent shares despite Dupixent sales boost

Sanofi's efforts to secure growth beyond 2030 once Dupixent loses patent exclusivity are being closely watched by investors. Recent setbacks have included the discontinuation of eczema drug amlitelimab, which led to a €952 million ($1.09 billion) impairment charge in the first half.

"The bigger Dupi gets, the bigger the hole is that Sanofi needs to fill when it loses patent protection," UBS analysts wrote.

The company said on Thursday that it would also scrap the development of lung treatment itepekimab and psoriasis drug balinatunfib.

"The strategic review of our late-stage pipeline is still ongoing," Garijo, who took charge in May, said, adding that she was no longer in a "diagnosis phase" and would maintain a fast pace of decision-making.